

Humira's Patent Wall


THE DRUG PATENT PROBLEM

Humira's patent wall lengthens its monopoly term by **19+ years**.

Americans will spend an estimated **\$99 billion** on Humira from when its main patent expires (2016) until biosimilar versions are introduced (2023).

PRICING, REVENUE, AND GROWTH FORECAST

Revenue for Humira in the U.S.



Indications: 11 total indications, major disease indications include rheumatoid arthritis (2003), psoriatic arthritis (2005), and Crohn's disease (2007)


Price: Current non-discounted annual price is \$44,000 per person

Trend: Price has increased over 100% from 2012 to 2018

CURRENTLY 39 YEARS OF PATENT PROTECTION

90% OF PATENT APPLICATIONS FILED AFTER FDA APPROVAL

- **257** patent applications filed, **130** granted
- Patents granted give commercial exclusivity for **39** years




DELAYED COMPETITION IN THE U.S.

Europe:

- Humira biosimilars launched in Europe in Oct 2018.
- Within six months, **prices dropped by 70%** and the five biosimilar products had captured over 1/3 of the total market share.

U.S.:

- AbbVie has reached settlement deals to delay the launch of biosimilars until 2023.
- An estimated **\$77 billion** will be spent on Humira in the U.S. from Oct 2018 until biosimilar entry in 2023.



THE COST OF OVERPATENTING

- AbbVie's 130 granted patents in the U.S. will prohibit biosimilars from entering the market until 2023.
- By contrast, AbbVie has only been granted six patents on Humira in Europe, where significantly lower-cost biosimilar versions of Humira have been available since 2018.
- The additional five years of monopoly protection will cost Americans an estimated \$77 billion.

More information on Humira is available at i-mak.org/humira